Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
株式のランク #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
株価
$0.00162013
最終同期: 2025-01-03
時価総額
$156.25K
変化(1日)
0.36%
変化(1年)
0.00%
SE
取引 Cyxone AB (publ) (CYXO)

カテゴリー

Cyxone AB (publ)(CYXO)の収益
Jun 2024 時点の収益 TTM: $196.92K
Cyxone AB (publ) の最新の財務報告によると、現在の収益 (TTM) は $196.92K です。2022 年には $613.68K の収益があり、これは 2021 年の 0.00 と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Cyxone AB (publ) の収益履歴(2015 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $196.92K -61.41%
2023 $510.29K -16.85%
2022 $613.68K 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $2.85K 2,442.71%
2018 $111.93 0.00%
2017 0.00 -100.00%
2016 $2.31K -7.16%
2015 $2.49K 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 6,410,780.38%
US
$6.02B 3,057,634.10%
NL
- -
CH
- -
KR
$10.11B 5,134,366.39%
BE